Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Pfizer and BioNTech seek U.S. authorization for omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine

By Brian Buntz | August 22, 2022

bivalent COVID-19 vaccine

[Image courtesy of Wikimedia Commons]

Pfizer (NYSE:PFE) and BioNTech (Nasdaq:BNTX) have filed paperwork with the FDA requesting Emergency Use Authorization (EUA) for an updated COVID-19 vaccine booster.

Specifically, the request relates to an omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

In late June, FDA recommended including an omicron BA.4/5 component for COVID-19 vaccine boosters.

Last week, the UK approved Moderna’s bivalent COVID-19 vaccine based on the original omicron lineage BA.1.

Pfizer and BioNTech are seeking authorization for a booster vaccine targeting the more recent sublineages omicron BA.4/BA.5.

If granted, the booster would be available for individuals at least 12 years old.

Pfizer and BioNTech note that the vaccine, if authorized, is available for immediate shipment.

The companies note that they plan on beginning a clinical trial focused on the omicron BA.4/BA.5-adapted bivalent vaccine candidate. The vaccine will analyze the vaccine’s safety, tolerability and immunogenicity.

The study would involve individuals 12 years of age and older.

FDA has signaled that it knows enough about the mRNA-based vaccines from Moderna, Pfizer and its partner BioNTech to authorize updated BA.4/BA.5-adapted boosters without new clinical trial data.

In June, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended updated COVID-19 vaccine boosters for the fall and winter months.

Pfizer and BioNTech have already studied their omicron BA.1-adapted bivalent vaccine in a Phase 2/3 study. Data from that study indicated that the updated booster generated a more robust immune response against the omicron BA.1 variant than the original BNT162b5 vaccine.

The Biden administration has signaled its intent to administer updated COVID-19 boosters in September.

After that, the administration will likely turn the bulk of responsibility for the COVID-19 response to the private sector.

PFE shares were mostly flat in mid-day trading, edging down 0.12% to $49.10.

Conversely, BNTZ shares were up about 1% to $149.35.

The BNT162b5 vaccine is already one of the bestselling pharmaceutical products in history. Last year, the vaccine generated $59.1 billion in total revenue between Pfizer and BioNTech.


Filed Under: clinical trials, Infectious Disease, Uncategorized
Tagged With: BA.4/BA.5-adapted bivalent vaccine, BioNTech, bivalent COVID-19 vaccine, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice 
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.   
FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE